The antibody drug conjugates market is projected to grow at an annualized rate of over 20%, till 2030
Key Market Insights
§ Eminentrepresentatives from different biopharmaceutical companies confirm thesustained interest in ADC therapeutics, highlighting the technologicalinnovation that is driving contemporary R&D initiatives
§ Presently, over 240 ADC therapy candidates are being evaluated inclinical / preclinical stages for treating a variety of solid tumors /hematologic cancers
§ The pipeline featuresproduct candidates that target a wide range of biological antigens and areequipped with different cytotoxic warheads; a number of companies are focused on developing novel drug conjugates
§ In order to gain acompetitive edge in the market, ADC developers are actively exploring newbiological targets, conducting clinical trials across different geographies totreat diverse disease indications
§ A number of eminent scientists from renowned universities, owing totheir involvement in clinical development efforts, have emerged as key opinionleaders within this market
§ Over the years, more than 16,000 patents related to ADCs have been filed/ granted across the world, indicative of the ongoing pace of R&D activityin this field of research
§ Several investors, having realized the opportunity within this upcomingsegment of targeted cancer therapeutics industry, have invested over USD 5billion, in the period between 2011 and 2019
§ The increasing interest in this field is also reflected in the partnershipactivity; deals inked in the recent past were mostly focused on licensing ofproducts / technologies, involving both international and indigenousstakeholders
§ In the recent years,several developer companies have initiated clinical trials to evaluate thetherapeutic potential of ADCs in combination with other drug / therapy classes
§ Anticipating the launch of several product candidates, stakeholders areexploring diverse commercialization strategies across different stages of thelaunch cycle along with the appropriate reimbursement strategies
§ Given thecomplexities associated with the development and production of ADCs, CMOs areindispensable to the R&D and manufacturing activity in this domain; someCMOs have even pioneered the novel ADC technology platforms
§ Case Study: In order to keep patients andhealthcare professionals informed and aware of the developments, companies aredeploying diverse promotional strategies for their respective products
§ With a promising development pipeline and encouraging clinical results,the global market is anticipated to witness growth at an annualized rate ofover 20% during the next decade
§ The anticipatedfuture opportunity is likely to be distributed across different types of linkers and target antigens as more late-stage drugs get commercialized andexisting marketing authorizations are expanded
For more information, please visit https://www.rootsanalysis.com/reports/view_document/antibody-drug-conjugates-market-5th-edition-2019-2030/270.html
Table of Contents
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Evolution of Anticancer Therapy
3.3. Cancer Treatment Methods
3.3.1. Surgery
3.3.2. Radiation Therapy
3.3.3. Chemotherapy
3.3.4. Targeted Therapies
3.4. Monoclonal Antibody-BasedAnticancer Therapies
3.5. Components of Antibody DrugConjugates (ADCs)
3.5.1. Antibody
3.5.2. Cytotoxin
3.5.3. Linker
3.6. Advantages of ADC Therapeutics overTraditional Therapeutic Interventions
3.7. Differences Between Small MoleculeDrugs, Monoclonal Antibody Therapies and ADCs
3.8. Pharmacokinetic Properties of ADCs
3.8.1. Absorption
3.8.2. Distribution
3.8.3. Metabolism and Excretion
4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. ADC Therapeutics: Clinical Pipeline
4.2.1. Analysis by Phase of Development
4.2.2. Analysis by Indication
4.2.3. Analysis by Line of Treatment
4.2.4. Analysis by Dosing Regimen
4.2.5. Analysis by Type of Therapy
4.2.6. Analysis by Target Antigen
4.2.7. Analysis by Antibody Origin
4.2.8. Analysis by Antibody Isotype
4.2.9. Analysis by Type of Linker
4.2.10. Analysis by Type of Payload /Warhead
4.2.11. Key Technology Providers
4.2.12. Discontinued Drugs
4.3. ADC Therapeutics: PreclinicalPipeline
4.3.1. Analysis by Phase of Development
4.3.2. Analysis by Indication
4.3.3. Analysis by Target Antigen
4.3.4. Key Players: Analysis by Numberof ADC Therapeutics
4.4. ADC Therapeutics: DeveloperLandscape
4.4.1. Analysis by Year of Establishment
4.4.2. Analysis by Company Size
4.4.3. Analysis by Geographical Location
4.4.4. Logo Landscape: Analysis by Sizeand Target Indication
4.5. Novel Drug Conjugates
5. COMPANY AND DRUG PROFILES
5.1. Chapter Overview
5.2. AbbVie
5.2.1. Company Overview
5.2.2. Financial Information
5.2.3. Pipeline Overview
5.2.3.1. Rovalpituzumab Tesirine /ROVA-T
5.2.3.1.1 Drug Overview
5.2.3.1.2. Mechanism of Action
5.2.3.1.3. Clinical Development Status
5.2.3.1.4. Key Clinical Trial Results
5.2.3.2. Teliso-V / TelisotuzumabVedotin / ABBV-399
5.2.3.2.1 Drug Overview
5.2.3.2.2. Mechanism of Action
5.2.3.2.3. Clinical Development Status
5.2.3.2.4. Key Clinical Trial Results
5.2.4. Recent Developments and FutureOutlook
5.3. Astellas Pharma
5.3.1. Company Overview
5.3.2. Financial Information
5.3.3. Pipeline Overview
5.3.3.1. Enfortumab Vedotin
5.3.3.1.1. Drug Overview
5.3.3.1.2. Mechanism of Action
5.3.3.1.3. Clinical Development Status
5.3.3.1.4. Key Clinical Trial Results
5.3.3.2. ASG16-M8F
5.3.3.2.1. Drug Overview
5.3.3.2.2. Mechanism of Action
5.3.3.2.3. Clinical Development Status
5.3.3.2.4. Key Clinical Trial Results
5.3.4. Recent Developments and FutureOutlook
5.4. AstraZeneca
54.1. Company Overview
5.4.2. Financial Information
5.4.3. Pipeline Overview
5.4.3.1. LUMOXITI™
5.4.3.1.1. Drug Overview
5.4.3.1.2. Mechanism of Action
5.4.3.1.3. Clinical Development Status
5.4.3.1.4. Key Clinical Trial Results
5.4.4. Recent Developments and FutureOutlook
5.5. Daiichi Sankyo
5.5.1. Company Overview
5.5.2. Financial Information
5.5.3. Pipeline Overview
5.5.3.1. Trastuzumab deruxtecan /DS-8201a / DS 8201
5.5.3.1.1. Drug Overview
5.5.3.1.2. Mechanism of Action
5.5.3.1.3. Clinical Development Status
5.5.3.1.4. Key Clinical Trial Results
5.5.4. Recent Developments and FutureOutlook
5.6. ImmunoGen
5.6.1. Company Overview
5.6.2. Financial Information
5.6.3. Pipeline Overview
5.6.3.1. IMGN853 / Mirvetuximabsoravtansine
5.6.3.1.1. Drug Overview
5.6.3.1.2. Mechanism of Action
5.6.3.1.3. Clinical Development Status
5.6.3.1.4. Key Clinical Trial Results
5.6.4. Recent Developments and FutureOutlook
5.7. Immunomedics
5.7.1. Company Overview
5.7.2. Financial Information
5.7.3. Pipeline Overview
5.7.3.1. IMMU-130
5.7.3.1.1. Drug Overview
5.7.3.1.2. Mechanism of Action
5.7.3.1.3. Clinical Development Status
5.7.3.1.4. Key Clinical Trial Results
5.7.4. Recent Developments and FutureOutlook
5.8. Pfizer
5.8.1. Company Overview
5.8.2. Financial Information
5.8.3. Pipeline Overview
5.8.3.1. CMC-544 / BESPONSA® /Inotuzumab Ozogamicin
5.8.3.1.1. Drug Overview
5.8.3.1.2. Mechanism of Action
5.8.3.1.3. Clinical Development Status
5.8.3.1.4. Key Clinical Trial Results
5.8.3.2. MYLOTARG™ / GemtuzumabOzogamicin
5.8.3.2.1. Drug Overview
5.8.3.2.2. Mechanism of Action
5.8.3.2.3. Clinical Development Status
5.8.3.2.4. Key Clinical Trial Results
5.8.4. Recent Developments and FutureOutlook
5.9. Roche / Genentech
5.9.1. Company Overview
5.9.2. Financial Information
5.9.3. Pipeline Overview
5.9.3.1. KADCYLA®
5.9.3.1.1. Drug Overview
5.9.3.1.2. Mechanism of Action
5.9.3.1.3. Clinical Development Status
5.9.3.1.4. Key Clinical Trial Results
5.9.3.2. RG-7596
5.9.3.2.1. Drug Overview
5.9.3.2.2. Mechanism of Action
5.9.3.2.3. Clinical Development Status
5.9.3.2.4. Key Clinical Trial Results
5.9.4. Recent Developments and FutureOutlook
5.10. Seattle Genetics
5.10.1. Company Overview
5.10.2. Financial Information
5.10.3. Pipeline Overview
5.10.3.1. ADCETRIS®
5.10.3.1.1. Drug Overview
5.10.3.1.2. Mechanism of Action
5.10.3.1.3. Clinical Development Status
5.10.3.1.4. Key Clinical Trial Results
5.10.3.2. SGN- LIV1A
5.10.3.2.1. Drug Overview
5.10.3.2.2. Mechanism of Action
5.10.3.2.3. Clinical Development Status
5.10.3.2.4. Key Clinical Trial Results
5.10.4. Recent Developments and FutureOutlook
5.11. Synthon
5.11.1. Company Overview
5.11.2. Financial Information
5.11.3. Pipeline Overview
5.11.3.1. SYD985 / TrastuzumabDuocarmazine
5.11.3.1.1. Drug Overview
5.11.3.1.2. Mechanism of Action
5.11.3.1.3. Clinical Development Status
5.11.3.1.4. Key Clinical Trial Results
5.11.4. Recent Developments and FutureOutlook
5.12. Other Companies
5.12.1. Bayer HealthCare
5.12.1.1. Company Overview
5.12.1.2. Financial Information
5.12.1.3. Pipeline Overview
5.12.1.4. Recent Developments and FutureOutlook
5.12.2. Biotest Pharmaceuticals
5.12.2.1. Company Overview
5.12.2.2. Financial Information
5.12.2.3. Pipeline Overview
5.12.2.4. Recent Developments and FutureOutlook
6. KEY THERAPEUTIC AREAS
6.1. Chapter Overview
6.2. Hematological Malignancies
6.2.1. Leukemias and Lymphomas
6.2.1.1. Leukemia: Introduction andEpidemiology
6.2.1.1.1. Acute Myeloid Leukemia
6.2.1.1.2. Chronic Myeloid Leukemia
6.2.1.1.3. Acute Lymphocytic Leukemia
6.2.1.1.4. Chronic Lymphocytic Leukemia
6.2.1.2. Lymphoma: Introduction andEpidemiology
6.2.1.3. Current Treatment Landscape
6.2.1.4. ADC Therapeutics for Leukemia /Lymphoma
6.2.2. Multiple Myeloma
6.2.2.1. Introduction and Epidemiology
6.2.2.2. Current Treatment Landscape
6.2.2.3. ADC Therapeutics for MultipleMyeloma
6.3. Solid Tumors
6.3.1. Lung Cancer
6.3.1.1. Introduction and Epidemiology
6.3.1.2. Current Treatment Landscape
6.3.1.3. ADC Therapeutics for LungCancer
6.3.2. Breast Cancer
6.3.2.1. Introduction and Epidemiology
6.3.2.2. Current Treatment Landscape
6.3.2.3. ADC Therapeutics for BreastCancer
6.3.3. Ovarian Cancer
6.3.3.1. Introduction and Epidemiology
6.3.3.2. Current Treatment Landscape
6.3.3.3. ADC Therapeutics for OvarianCancer
6.3.4. Bladder Cancer
6.3.4.1. Introduction and Epidemiology
6.3.4.2. Current Treatment Landscape
6.3.4.3. ADC Therapeutics for BladderCancer
6.3.5. Colorectal Cancer
6.3.5.1. Introduction and Epidemiology
6.3.5.2. Current Treatment Landscape
6.3.5.3. ADC Therapeutics for ColorectalCancer
6.3.6. Prostate Cancer
6.3.6.1. Introduction and Epidemiology
6.3.6.2. Current Treatment Landscape
6.3.6.3. ADC Therapeutics for ProstateCancer
6.3.7. Gastric Cancer
6.3.7.1. Introduction and Epidemiology
6.3.7.2. Current Treatment Landscape
6.3.7.3. ADC Therapeutics for ProstateCancer
7. KEY OPINION LEADERS
7.1. Chapter Overview
7.2. Methodology
7.3. Principal Investigators /Sub-Investigators / Study Directors Involved in Clinical Trials
7.3.1. Geographical Distribution of KeyOpinion Leaders
7.3.1.1. Experts on ADCETRIS®
7.3.1.2. Experts on KADCYLA®
7.3.1.3. Experts on MYLOTARG™
7.3.1.4. Experts on Other ADCs
7.4. Prominent Key Opinion Leaders(KOLs)
7.5. KOL Benchmarking: Roots Analysisversus Third Party Scoring (ResearchGate Score)
7.6. Most Active Key Opinion Leaders
7.6.1. Profile: KOL A (Celgene)
7.6.2. Profile: KOL B (Western RegionalMedical Center)
7.6.3. Profile: KOL C (MedStarWashington Hospital Center)
7.6.4. Profile: KOL D (Cancer Instituteand Hospital)
7.6.5. Profile: KOL E (ComprehensiveCancer Centers of Nevada)
7.6.6. Profile: KOL F (Hopital Tenon)
7.6.7. Profile: KOL G (Cleveland Clinic)
8. TARGET COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Competitiveness Analysis: Key ClinicalTargets for ADCs
8.3.1. Four-Dimensional Bubble Analysis
8.3.2 Five-Dimensional Spider WebAnalysis
8.4. Competitiveness Analysis: KeyPreclinical Targets for ADCs
8.4.1. Two-Dimensional Scatter PlotAnalysis
9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. ADC Therapeutics: List ofPartnerships and Collaborations
9.3.1 Analysis by Year of Partnerships
9.3.2. Analysis by Type of Partnerships
9.3.3. Most Active Players: Analysis byNumber of Partnerships
9.3.4. Regional Analysis
9.3.4.1. Intercontinental andIntracontinental Agreements
10. FUNDING AND INVESTMENT ANALYSIS
10.1. Chapter Overview
10.2. Types of Funding
10.3. ADC Therapeutics: Funding andInvestment Analysis
10.3.1. Analysis by Number of Instances
10.3.2. Analysis by Amount Invested
10.3.3. High Value Deals: Analysis byYear
10.3.4. Analysis by Type of Funding
10.3.5. Most Active Players
10.3.5.1. Analysis by Number of FundingInstances
10.3.5.2. Analysis by Amount Invested
10.4. Concluding Remarks
11. PATENT ANALYSIS
11 Patent Analysis
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. ADC Therapeutics: Patent Analysis
11.3.1. Analysis by Publication Year
11.3.2. Analysis by GeographicalLocation
11.3.3. Analysis by CPC Classification
11.3.4. Emerging Focus Areas
11.3.5. Analysis by Type of Industry
11.3.6. Leading Players: Analysis byNumber of Patents
11.4. ADC Therapeutics: PatentBenchmarking Analysis (Industry Players)
11.4.1. Analysis by PatentCharacteristics
11.4.2. Analysis By GeographicalLocation
11.5. ADC Therapeutics: Patent ValuationAnalysis
12. ACADEMIC GRANTS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. ADC Therapeutics: List of AcademicGrants
12.3.1. Analysis by Number of Grants
12.3.2. Analysis by Type of Grant
12.3.3. Analysis by Grant Amount
12.3.4. Analysis by Focus Area
12.3.5. Analysis by Support Period
12.4. Leading Organizations: Analysis byNumber of Grants
12.5. Analysis by Type of RecipientOrganization
12.6. Analysis by AdministeringInstitute Center
12.7. Analysis by Funding InstituteCenter
12.8. Key Project Leaders: Analysis byNumber of Grants
13. KEY COMMMERCIALIZATION STRATEGIES
13.1. Chapter Overview
13.2. Successful Drug Launch Strategy:ROOTS Framework
13.3. Successful Drug Launch Strategy:Product Differentiation
13.4. Common CommercializationStrategies Adopted Based on Development Stage of Product
13.5. Approved Molecules for ADCs
13.5.1. ADCETRIS®
13.5.2. KADCYLA®
13.5.3. MYLOTARG™
13.5.4. BESPONSA®
13.5.5. LUMOXITI™
13.5.5. POLIVY™
13.6. Key Commercialization StrategiesAdopted by Companies Developing ADCs
13.6.1. Strategies Adopted Before DrugApproval
13.6.1.2. Collaboration with InternalStakeholders and Pharmaceutical Firms
13.6.2. Strategies Adopted During / PostDrug Approval
13.6.2.1. Geographical Expansion
13.6.2.2. Participation in Global Events
13.6.2.3. Awareness Through ProductWebsites
13.6.2.4. Collaboration with InternalStakeholders and Pharmaceutical Firms
13.7. Concluding Remarks
14. PROMOTIONAL ANALYSIS
14.1. Chapter Overview
14.2. Channels Used for PromotionalCampaigns
14.3. Summary of Product WebsiteAnalysis
14.4. Summary of Patient Brochure andInformative Downloads
14.5. ADCETRIS®: Promotional Analysis
14.5.1. Product Website Analysis
14.5.1.1. Messages for HealthcareProfessionals
14.5.1.2. Messages For Patients
14.5.2. Patient Support Services andInformative Downloads
14.5.3. Other Promotional Activities
14.5.3.1. Presence in Conferences
14.6. KADCYLA®: Promotional Analysis
14.6.1. Product Website Analysis
14.6.1.1. Messages for HealthcareProfessionals
14.6.1.2. Messages for Patients
14.6.2. Patient Support Services andInformative Downloads
14.6.3. Other Promotional Activities
14.6.3.1. Presence in Conferences
14.7. MYLOTARG™: Promotional Analysis
14.7.1. Product Website Analysis
14.7.1.1. Messages for HealthcareProfessionals
14.7.1.2. Messages for Patients
14.7.2. Patient Support Services andInformative Downloads
14.7.3. Other Promotional Activities
14.7.3.1. Presence in Conferences
14.8. BESPONSA®: Promotional Analysis
14.8.1. Product Website Analysis
14.8.1.1. Messages for HealthcareProfessionals
14.8.1.2. Messages for Patients
14.8.2. Patient Support Services andInformative Downloads
14.8.3. Other Promotional Activities
14.8.3.1. Presence in Conferences
14.9. LUMOXITI™: Promotional Analysis
14.9.1. Product Website Analysis
14.9.1.1. Messages for HealthcareProfessionals
14.9.1.2. Messages for Patients
14.9.2. Patient Support Services andInformative Downloads
14.9.3. Other Promotional Activities
14.9.3.1. Presence in Conferences
14.10. POLIVY™: Promotional Analysis
14.10.1. Product Website Analysis
14.10.1.1. Messages for HealthcareProfessionals
14.10.1.2. Messages for Patients
14.10.2. Patient Support Services andInformative Downloads
14.10.3. Other Promotional Activities
14.10.3.1. Presence in Conferences
15. COMBINATION THERAPIES
15.1. Chapter Overview
15.2. Combination Therapy: History ofDevelopment
15.3. FDA-approved Combination Therapiesin Oncology
15.4. Combination Therapy: FDAGuidelines
15.4.1. Combinations of Marketed Drugs
15.4.2. Combinations of Marketed Drugswith New Molecular Entities
15.4.3. Combinations of New MolecularEntities
15.5. Combination Therapies: ADCs
15.5.1. Completed / Ongoing ClinicalStudies of ADCs
15.5.1.1. Analysis by Type of Therapy
15.5.2. Completed / Ongoing ClinicalStudies of ADC-based Combination Therapies
15.5.2.1. Analysis by Highest Phase of Development
15.5.2.2. Analysis by Current TrialStatus
15.5.2.3. Analysis by Type ofCombination
15.5.2.4. Analysis by Indication andType of Combination
16. NOVEL CONJUGATION TECHNOLOGY PLATFORMS
16.1. Chapter Overview
16.2. First Generation ADC Technologies
16.3. Second Generation ADC Technologies
16.3.1. Cysteine and SelenocysteineEngineering
16.3.2. Unnatural Amino Acid Engineering
16.3.3. Amino-Terminal Engineered Serine
16.4. Third Generation ADC Technologies
16.4.1. Enzyme-Assisted Ligation Approaches
16.4.2. Glycan Remodeling Approaches
16.4.3. Ligation at FabNucleotide-Binding Site
16.4.4. Cysteine Rebridging
16.4.5. Preventing / LimitingRetro-Michael Drug Deconjugation
16.5. Evolutionary Analysis ofConjugation Technologies
17. ASSESMENT OF NON-CLINICAL DATA, FIRST IN HUMAN DOSING
17.1. Chapter Overview
17.2. ADCs and Non-Clinical Studies
17.3. ICH S9 Guidelines
17.4. Investigational New Drug(IND)-Enabling Study Designs
17.4.1. Example Case: KADCYLA®
17.5. Toxicities in Animal Models
17.6. Prediction of Maximum ToleratedDosage (MTD) in Humans
17.7. Other Key Considerations for StudyDesign
18. COST PRICE ANALYSIS
18.1. Chapter Overview
18.2. Factors Contributing Towards theHigh Price of ADC Therapeutics
18.3. ADC Therapeutics Market: PricingModels
18.3.1. On the Basis of Associated Costs
18.3.2. On the Basis of Competition
18.3.3. On the Basis of Patient Segment
18.4. Reimbursement Considerations forADC Therapeutics
19. CASE STUDY: CONTRACT MANUFACTURING OF ADC
19.1. Chapter Overview
19.2. Key Steps for ADC Manufacturing
19.3. Technical Concerns Related to ADCManufacturing
19.4. Challenges Associated with SupplyChain and Method Transfer
19.5. Limitations of In-HouseManufacturing
19.6. Investments in ADC ManufacturingCapability Expansions
19.7. Collaborations Established for ADCManufacturing
19.8. Growing Demand for ContractManufacturing
19.9. Emergence of Start-Ups OfferingContract Services
19.10. CMOs with Linker ManufacturingCapabilities
19.11. CMOs with HPAPI / CytotoxicPayload Manufacturing Capabilities
19.12. CMOs with ConjugationCapabilities
19.13. ADC One Stop Shops
20. CASE STUDY: COMPANION DIAGNOSTICS FOR ADC THERAPEUTICS
20.1. Chapter Overview
20.1.1. Advantages of CompanionDiagnostics
20.1.2. Disadvantages of CompanionDiagnostics
20.2. Companion Diagnostics for ADCTherapeutics
20.3. ADC Therapeutics: List ofCompanion Diagnostics
20.3.1. Analysis by Type of Target
20.3.2. Analysis by Type of CancerIndication
20.4. Concluding Remarks
21. MARKET FORECAST AND OPPORTUNITY ANALYSIS
21.1. Chapter Overview
21.2. Scope and Limitations
21.3. Forecast Methodology
21.4. Overall ADC Therapeutics Market
21.4.1. ADC Therapeutics Market:Distribution by Target Indication
21.4.2. ADC Therapeutics Market:Distribution by Type of Linker
21.4.3. ADC Therapeutics Market:Distribution by Type of Payload
21.4.4. ADC Therapeutics Market:Distribution by Target Antigen
21.4.5. ADC Therapeutics Market:Distribution by Geography
21.4.6. ADC Therapeutics Market:Distribution by Technology Providers
21.5. ADC Therapeutics Market:Individual Drug Sales Forecasts
21.5.1. ADCETRIS® / Brentuximab Vedotin
21.5.1.1. Target Patient Population
21.5.1.2. Sales Forecast
21.5.2. KADCYLA® / Ado-trastuzumabEmtansine
21.5.2.1. Target Patient Population
21.5.2.2. Sales Forecast
21.5.3. MYLOTARG™ / GemtuzumabOzogamicin
21.5.3.1. Target Patient Population
21.5.3.2. Sales Forecast
21.5.4. BESPONSA® / InotuzumabOzogamicin
21.5.4.1. Target Patient Population
21.5.4.2. Sales Forecast
21.5.5. LUMOXITI™
21.5.5.1. Target Patient Population
21.5.5.2. Sales Forecast
21.5.6. POLIVYTM / Polatuzumabvedotin-piiq / RG7596
21.5.6.1. Target Patient Population
21.5.6.2. Sales Forecast
21.5.7. ASG-22ME / Enfortumab Vedotin
21.5.7.1. Target Patient Population
21.5.7.2. Sales Forecast
21.5.8. BAT8001
21.5.8.1. Target Patient Population
21.5.8.2. Sales Forecast
21.5.9. DS-8201a / DS 8201 / TrastuzumabDeruxtecan
21.5.9.1. Target Patient Population
21.5.9.2. Sales Forecast
21.5.10. IMMU-132 / SacituzumabGovitecan
21.5.10.1. Target Patient Population
21.5.10.2. Sales Forecast
21.5.11. IMGN853 / MirvetuximabSoravtansine
21.5.11.1. Target Patient Population
21.5.11.2. Sales Forecast
21.5.12. lpituzumab TesirineRova-T /Rova
21.5.12.1. Target Patient Population
21.5.12.2. Sales Forecast
21.5.13. SYD985 / TrastuzumabDuocarmazine
21.5.13.1. Target Patient Population
21.5.13.2. Sales Forecast
21.5.14. ABBV-399 / Teliso-V /Telisotuzumab Vedotin
21.5.14.1. Target Patient Population
21.5.14.2. Sales Forecast
21.5.15. ADCT-301 / HuMax-TAC-ADC /Camidanlumab Tesirine
21.5.15.1. Target Patient Population
21.5.15.2. Sales Forecast
21.5.16. ADCT-402 / LoncastuximabTesirine
21.5.16.1. Target Patient Population
21.5.16.2. Sales Forecast
21.5.17. AGS 16M8F / AGS 16C3F
21.5.17.1. Target Patient Population
21.5.17.2. Sales Forecast
21.5.18. AVID100
21.5.18.1. Target Patient Population
21.5.18.2. Sales Forecast
21.5.19. BAY 94-9343
21.5.19.1. Target Patient Population
21.5.19.2. Sales Forecast
21.5.20. GSK 2857916 / Anti-BCMA ADC
21.5.20.1. Target Patient Population
21.5.20.2. Sales Forecast
21.5.21. HuMax-TF-ADC / TisotumabVedotin
21.5.21.1. Target Patient Population
21.5.21.2. Sales Forecast
21.5.22. IMGN529 / Debio 1562 /Naratuximab Emtansine
21.5.22.1. Target Patient Population
21.5.22.2. Sales Forecast
21.5.23. IMMU-130 / SacituzumabGovitecan
21.5.23.1. Target Patient Population
21.5.23.2. Sales Forecast
21.5.24. RC48
21.5.24.1. Target Patient Population
21.5.24.2. Sales Forecast
21.5.25. SGN-LIV1A / LadiratuzumabVedotin
21.5.25.1. Target Patient Population
21.5.25.2. Sales Forecast
22. SWOT ANALYSIS
22.1. Chapter Overview
22.2. Strengths
22.3. Weaknesses
22.4. Opportunities
22.5. Threats
22.6. Comparison of SWOT Factors
22.7. Concluding Remarks
23. CONCLUSION
23.1. Chapter Overview
23.2. Key Takeaways
24. EXECUTIVE INSIGHTS
24.1. Chapter Overview
24.2. Abzena
24.2.1. Company Snapshot
24.2.2. Interview Transcript: John Burt,Chief Executive Officer
24.3. Ajinomoto Bio-Pharma Services
24.3.1. Company Snapshot
24.3.2. Interview Transcript: TatsuyaOkuzumi, Associate General Manager
24.4. BSP Pharmaceuticals
24.4.1. Company Snapshot
24.4.2. Interview Transcript: AldoBraca, President and Chief Executive Officer and Giorgio Salciarini, TechnicalBusiness Development Senior Manager
24.5. Catalent Pharma Solutions
24.5.1. Company Snapshot
24.5.2. Interview Transcript: JenniferL. Mitcham, Director, SMARTag ADCs and Bioconjugates, and Stacy McDonald, GroupProduct Manager
24.6. Cardiff University
24.6.1. Company Snapshot
24.6.2. Interview Transcript: AlanBurnett, Professor, School of Medicine
24.7. Cerbios-Pharma
24.7.1. Company Snapshot
24.7.2. Interview Transcript: DenisAngioletti, Chief Commercial Officer
24.8. Eisai
24.8.1. Company Snapshot
24.8.2. Interview Transcript: ToshimitsuUenaka, Executive Director and Takashi Owa, Chief Innovation Officer
24.9. Lonza
24.9.1. Company Snapshot
24.9.2. Interview Transcript: LaurentDucry, Head of Bioconjugates Commercial Development
24.10. NBE-Therapeutics
24.10.1. Company Snapshot
24.10.2. Interview Transcript: WouterVerhoeven, Chief Business Officer
24.11. Oxford BioTherapeutics
24.11.1. Company Snapshot
24.11.2. Interview Transcript: ChristianRohlff, Chief Executive Officer and Founder
24.12. Pierre Fabre
24.12.1. Company Snapshot
24.12.2. Interview Transcript: ChristianBailly, Director of CDMO
24.13. Piramal Healthcare
24.13.1. Company Snapshot
24.13.2. Interview Transcript: MarkWright, Site Head, Grangemouth
24.14. Synaffix
24.14.1. Company Snapshot
24.14.2. Interview Transcript: AnthonyDeBoer, Director, Business Development
24.15. Syndivia
24.15.1. Company Snapshot
24.15.2. Interview Transcript: SashaKoniev, Chief Executive Officer and Co-Founder
24.16. Anonymous, Director, BusinessDevelopment, Leading CMO
24.17. Anonymous, Chief ExecutiveOfficer, Leading CMO
25. APPENDIX 1: TABULATED DATA
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
